HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Bial bails after Parkinson's fail, axing asset over phase 2 miss

Bial has stopped development in a subpopulation of Parkinson's disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.

By FierceBiotech · Jun 9, 2026 · via FierceBiotech
Bial bails after Parkinson's fail, axing asset over phase 2 miss

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The Oral GLP-1 Tracker: Novo's oral Wegovy hits 3M prescription milestone as Lilly's Foundayo chugs along in early launch
The WeekFiercePharma ↗
The Oral GLP-1 Tracker: Novo's oral Wegovy hits 3M prescription milestone as Lilly's Foundayo chugs along in early launch
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…
Jun 9, 2026
ResMed buys Noctrix Health for $340M, widening its sleep-tech reach
The WeekBriefing
ResMed buys Noctrix Health for $340M, widening its sleep-tech reach
The sleep and respiratory giant completed the $340M Noctrix acquisition, adding a wearable neuromodulation tre…
Jun 9, 2026
The WeekDrug Channels ↗
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: 340B in 2026: …
Jun 9, 2026